You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mechanical generation of peri-valvular oscillatory flow to prevent deep venous thrombosis.

    SBC: OSCIFLEX LLC            Topic: NHLBI

    Project SummaryDeep venous thrombosisDVTand secondary pulmonary embolismPEaffectof the population and cause approximatelydeaths annually in the USImmobility and lack of muscular activity is the primary risk factor for DVTan effect attributed to reduced venous flowAutopsy studies have identified the venous valve sinus in the leg as the site of origin for DVTbut a molecular and cellular mechanism fo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a tracheal sound sensor for early detection of hypoventilation due to opioid overdose.

    SBC: RTM Vital Signs, LLC            Topic: R41

    Abstract More thanAmericans died from drug overdose inand drug overdose is now the most common cause of death for people underyears old in the United StatesFurthermorethe number of overdose deaths is increasing with the rise of abuse of powerful synthetic opioidssuch as fentanylIn May ofNational Institutes of HealthNIHand National Institute on Drug AbuseNIDAdirectors DrsCollins and Volkow outlined ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIDCR

    Kaposi SarcomaKSis the most common cancer in themillion worldwide AIDS populationKS tumors are caused by Kaposi Sarcoma Associated Herpes VirusKSHVEven though HAART therapy has resulted in a dramatic decline in KS in the USthis malignancy remains the most predominant tumor of AIDSParadoxicallyKS tumors arise in some AIDS patients following HAART treatmentdue to Immune Reconstitution Inflammatory S ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Serum Inflammasome proteins: Novel biomarker panel for radiation biodosimetry

    SBC: JT-MESH DIAGNOSTICS LLC            Topic: NIEHS

    JT MeSh diagnostics is developing novel biodosimeter devices which will allow for rapidsimpleon site mass screening in the event of a nuclear disaster or an act of terrorismdirty bombBiodosimeters are critical in the event of a large scale radiological emergencyin the form of a nuclear disasterterrorist attack or radiation exposure of military personnelwhere a large population ofexposedindividuals ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Small-molecule combinationsexpand hematopoietic stem cell ex vivo and in vivo

    SBC: Advac Therapeutic LLC            Topic: NHLBI

    Small-molecule combinations expand hematopoietic stem cell ex vivo and in vivo Abstract Hematopoietic stem cells (HSCs) are featured by their self-renewal potential and ability to differentiate into multiple blood lineages. Hematopoietic stem cell transplant (HSCT) is a mainstay of life-saving therapy for hematopoietic malignancies and hypoproliferative disorders. The use of noninvasively accessib ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. IND enabling development of LGM2605 as adjuvant treatment for asthma

    SBC: Lignamed, LLC            Topic: NIAID

    Project summary IND enabling development of LGM2605 as adjuvant treatment for asthma Glucocorticoid resistance is a major treatment problem in asthma. Our recent studies in mice, non-human primates and severe asthma patients, along with reports by others suggest that glucocorticoid receptor (GR) expression was impaired by psychosocial stress, in association with enhanced NF-kB activation and gluco ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Associating Clinical Decision Support Use with Clinical Outcomes in a Visual Analytics Display

    SBC: PHRASE HEALTH, INC.            Topic: NLM

    Project Summary Abstract Clinical decision supportCDSis a process for enhancing health related decisions and actions with pertinentorganized clinical knowledge and patient information to improve healthcare deliveryFor exampledoctors may have trouble remembering to order all guideline recommended care for sepsisCDS delivered via an order set in the electronic health recordEHRcan simplify this proce ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Customer discovery for minimally invasive nerve block device to treat severe pain and reduce usage of opiates

    SBC: Thermaquil, Inc.            Topic: 106

    Abstract: Thoracotomy is one of the most painful surgical procedures and patients are at high risk of developing opioid addiction. Recent studies have shown 1 in 7 patients became new persistent opioid users after physical recovery from the surgery was complete. The largest risk factor for opioid addiction is being prescribed opioids in the first place, and Thermaquil wants to reduce this incidenc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer’s disease (AD) and related dementias are increasing rapidly yet, remarkably, there are no approved disease modifying drugs. Virtually all trials targeting amyloid related pathways have failed over the last 10 years. Regrettably, few alternative targets or pathways have been explored. Therefore, there is an urgent need to explore alternative pathways as monotherapies or as cons ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Prevention of renarcotization from synthetic opioids

    SBC: CONSEGNA PHARMA INC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT In October 2017, the U.S. Government declared the current opioid epidemic the worst drug crisis in American history. Synthetically derived opioids such as fentanyl and fentanyl-derivatives have been at the forefront of this public health emergency, exhibiting the highest year-to-year contribution to overdose deaths. While the mu opioid receptor (MOR) antagonist naloxone ha ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government